TABLE 3.

Cancer incidence rates and hazard ratios for histologically defined EoE patients and general population controls.

	IR EoE/1000 person‐years	IR general population	aHR [95% CI]
		Reference individuals/1000 person‐years
Total	3.9 [3.0–5.1]	3.2 [2.8–3.7]	1.11 [0.80–1.53]
Sex
Males	3.5 [2.5–4.9]	2.9 [2.4–3.4]	1.14 [0.77–1.68]
Females	5.2 [3.1–8.1]	4.3 [3.3–5.5]	1.12 [0.63–1.97]
Follow up (years)
< 1	6.4 [3.5–10.9]	3.7 [2.6–5.3]	1.54 [0.75–3.18]
1 < 5	3.1 [2.0–4.7]	3.0 [2.5–3.7]	0.96 [0.58–1.59]
5 < 10	3.8 [2.3–6.1]	3.2 [2.4–4.1]	1.08 [0.60–1.95]
≥ 10	6.3 [2.6–13.8]	4.0 [2.4–6.5]	1.30 [0.39–4.38]
Age at start follow up (years)
< 18	0.3 [0.1–1.2]	0.2 [0.1–0.5]	1.81 [0.19–17.42]
18–49	2.3 [1.4–3.7]	1.9 [1.4–2.4]	1.21 [0.65–2.24]
≥ 50	10.5 [7.5–14.4]	9.2 [7.8–10.9]	1.09 [0.74–1.60]
Year of start follow up
1990–2005	12.4 [6.1–23.1]	4.8 [2.9–7.6]	3.19 [1.20–8.51]
2006–2013	3.4 [2.3–4.9]	3.4 [2.8–4.0]	0.93 [0.60–1.43]
2014–2017	3.7 [2.3–5.8]	2.7 [2.0–3.5]	1.26 [0.70–2.24]
Country
Nordic	4.0 [3.0–5.2]	3.5 [3.0–4.0]	1.06 [0.76–1.48]
Non‐Nordic	3.6 [1.1–10.1]	1.7 [1.0–2.6]	NA [NA–NA]
Education (years)
Compulsory school (≤ 9)	5.7 [3.1–9.7]	3.7 [2.7–5.0]	1.45 [0.58–3.59]
Upper secondary school (10–12)	4.7 [3.1–7.0]	4.3 [3.4–5.2]	0.94 [0.54–1.65]
College or university (≥ 13)	4.6 [2.9–7.1]	3.8 [2.9–5.0]	1.13 [0.56–2.28]
Missing data	0.4 [0.1–1.5]	0.5 [0.2–0.9]	2.55 [0.23–28.14]

Note: NA values could not be calculated due to insufficient data.

Abbreviations: aHR, adjusted hazard ratio; EoE, eosinophilic esophagitis; IR, incidence rate.